Research progress of non-coding RNA in gastrointestinal stromal tumor / 中国癌症杂志
China Oncology
;
(12): 392-396, 2015.
Article
in Chinese
| WPRIM
| ID: wpr-463344
ABSTRACT
Gastrointestinal stromal tumor (GIST) is the most common gastrointestinal mesenchymal tumors, mainly due to the onset of the proto-oncogene receptor tyrosine kinase, or platelet-derived growth factor receptor gene activating mutations. Molecular targeted therapy drug of imatinib mesylate inhibit KIT, platelet-derived growth factor receptor aloha (PDGFRA) gene tyrosine kinase activity, which is effective in patients with advanced GIST. However, a growing number of studies have found the presence of imatinib mesylate in primary and secondary drug resistance in the treatment of GIST process. With the in-depth study of the physiological function and mechanism of action of non-coding RNA in recent years, making it gradually realized extensive regulation of non-coding RNA gene expression, which occurs in tumor development, invasion and metastasis, drug resistance and other processes plays an important role. Non-coding RNA has the potential to explore GIST pathogenesis and resistance mechanisms to provide new ideas and direction.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
China Oncology
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS